NCT00039234Unknown3 期
A Phase III, Multi-Center Controlled Trial With Stratified Randomization Comparing The Efficacy Of Interleukin-2 (IL-2) Plus Histamine Dihydrochloride (HDC) Versus IL-2 Alone To Increase The Duration Of Survival In Patients With AJCC Stage IV Malignant Melanoma With Hepatic Metastasis
Maxim Pharmaceuticals36 个研究点 分布在 4 个国家开始时间: 2002年9月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 发起方
- 试验地点
- 36
研究概览
简要总结
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Histamine dihydrochloride may help interleukin-2 kill more tumor cells by making tumor cells more sensitive to the drug. It is not yet known if interleukin-2 is more effective with or without histamine dihydrochloride in treating stage IV melanoma that is metastatic to the liver.
PURPOSE: Randomized phase III trial to compare the effectiveness of interleukin-2 with or without histamine dihydrochloride in treating patients who have stage IV melanoma that is metastatic to the liver.
详细描述
OBJECTIVES:
- Compare the duration of survival in patients with stage IV melanoma with hepatic metastasis treated with interleukin-2 with or without histamine dihydrochloride.
- Compare the progression-free survival, response rate, response rate of hepatic tumors, and lack of disease progression in patients treated with these regimens.
- Determine the safety of these regimens, in terms of frequency, severity, and causal relationship of adverse events, in these patients.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center location (North America vs Europe), lactate dehydrogenase (less than ULN vs ULN or greater), and metastatic sites (liver only vs liver and other sites). Patients are randomized to one of two treatment arms.
- Arm I: Patients receive interleukin-2 (IL-2) subcutaneously (SC) twice daily on days 1 and 2 of weeks 1 and 3 and days 1-5 of weeks 2 and 4. Patients also receive histamine dihydrochloride SC over 10-30 minutes on days 1-5 of weeks 1-4.
- Arm II: Patients receive IL-2 as in arm I. In both arms, treatment repeats every 6 weeks for at least 8 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 3 years and then every 6 months thereafter.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed stage IV melanoma
- •Must have radiological evidence of lesions in liver (target or non-target)
- •At least 1 measurable lesion outside previously irradiated field
- •At least 20 mm by contrast-enhanced CT scan, MRI, medical photography, or physical exam OR at least 10 mm by spiral CT scan
- •No prior or concurrent clinical and/or objective evidence of brain metastasis
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Performance status:
- •Life expectancy:
- •At least 3 months
- •Hematopoietic:
- •Hemoglobin at least 9.5 g/dL
- •WBC at least 3,000/mm^3
- •Granulocyte count at least 2,000/mm^3
- •Platelet count at least 100,000/mm^3
- •Bilirubin no greater than 2 times upper limit of normal (ULN)
- •AST and ALT no greater than 4 times ULN
- •Alkaline phosphatase no greater than 4 times ULN
- •Hepatitis B and C negative
- •Creatinine no greater than 1.7 mg/dL
- •Calcium no greater than 11.5 mg/dL
- •Cardiovascular:
- •No abnormal thallium stress test
- •No acute myocardial infarction within the past year
- •No New York Heart Association class III or IV heart disease
- •No asthma requiring active treatment within the past 5 years
- •Oxygen saturation by pulse oximeter at least 90% unless FEV_1 is greater than 2 L or at least 75% predicted
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •HIV negative
- •Concurrent medically-controlled (except with glyburide) or diet-controlled diabetes is allowed
- •Concurrent medically-controlled thyroid dysfunction is allowed
- •No other active malignancy within the past 5 years except carcinoma in situ of the cervix or localized squamous cell or basal cell skin cancer
- •No serious non-malignant medical conditions, including psychiatric disability, that would preclude study compliance
- •No active autoimmune disease (e.g., lupus, inflammatory bowel disease, or psoriasis)
- •No active peptic and/or esophageal ulcer disease
- •No hypersensitivity to histamine products or urticaria
- •No active IV drug abuse
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy:
- •No prior immunotherapy with high-dose IV interleukin-2 (IL-2)
- •No prior combination immunotherapy with chemotherapy
- •At least 1 year since prior low-dose adjuvant IL-2 as part of vaccine therapy or as therapy for stage II or III melanoma
- •Chemotherapy:
- •See Biologic therapy
- •Endocrine therapy:
- •No chronic systemic glucocorticoid steroids
- •Asthma inhalers, topical creams, or intra-articular injections allowed
- 另有 17 项未显示
排除标准
- 未提供
研究者
研究点 (36)
Loading locations...
相似试验
已完成
2 期
Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney CancerRecurrent Renal Cell CancerStage III Renal Cell CancerStage IV Renal Cell CancerNCT00032188National Cancer Institute (NCI)65
已完成
1 期
Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous TreatmentKidney CancerLung CancerBladder CancerNCT00016237EMD Serono
已完成
1 期
Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid TumorsUnspecified Adult Solid Tumor, Protocol SpecificNCT00002994Alliance for Clinical Trials in Oncology355
Unknown
3 期
Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or OropharynxHead and Neck CancerNCT00002702European Institute of Oncology260
已完成
3 期
Interleukin-2 in Treating Patients With Metastatic Kidney CancerKidney CancerNCT00018941National Cancer Institute (NCI)